Exscientia plc (NASDAQ:EXAI - Get Free Report) traded down 2.8% on Monday . The company traded as low as $5.11 and last traded at $5.17. 192,023 shares changed hands during trading, a decline of 70% from the average session volume of 631,275 shares. The stock had previously closed at $5.32.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the company. Morgan Stanley reiterated an "equal weight" rating and set a $7.00 price objective on shares of Exscientia in a research note on Monday, April 22nd. Barclays reiterated an "equal weight" rating and set a $5.00 price objective on shares of Exscientia in a research note on Tuesday, August 13th. Finally, TD Cowen restated a "hold" rating on shares of Exscientia in a research note on Friday, August 9th.
Check Out Our Latest Report on EXAI
Exscientia Trading Up 3.2 %
The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.30 and a current ratio of 6.30. The company has a 50 day moving average of $5.21 and a two-hundred day moving average of $5.39. The stock has a market cap of $663.67 million, a PE ratio of -4.02 and a beta of 0.85.
Exscientia (NASDAQ:EXAI - Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.05). Exscientia had a negative net margin of 666.80% and a negative return on equity of 34.59%. The business had revenue of $5.60 million during the quarter. Sell-side analysts anticipate that Exscientia plc will post -1.12 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Exscientia
A number of hedge funds have recently made changes to their positions in EXAI. GAMMA Investing LLC raised its holdings in shares of Exscientia by 112.1% during the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company's stock valued at $25,000 after acquiring an additional 2,302 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Exscientia by 76.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,274 shares of the company's stock valued at $53,000 after purchasing an additional 4,029 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Exscientia in the second quarter valued at approximately $54,000. Walled Lake Planning & Wealth Management LLC purchased a new stake in shares of Exscientia in the fourth quarter valued at approximately $64,000. Finally, Federated Hermes Inc. purchased a new stake in shares of Exscientia in the second quarter valued at approximately $115,000. Institutional investors and hedge funds own 41.58% of the company's stock.
Exscientia Company Profile
(
Get Free Report)
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
Featured Articles
Before you consider Exscientia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exscientia wasn't on the list.
While Exscientia currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
